1-4 of 4
Keywords: Leuprorelin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)

Open Access
Subject Area:
Further Areas
Bernd J. Schmitz-Dräger, Ekkehardt Bismarck, Thomas Ebert, Roland Starlinger, Kerstin Dienes, Bertram Ottillinger, Peter J. Goebell, Stephan Mühlich, Natalya Benderska-Söder, Jutta Bergler-Klein, Oliver W. Hakenberg
Journal: Urologia Internationalis
Urol Int (2025)
https://doi.org/10.1159/000543985
Published Online: 20 February 2025
... study in patients with locally advanced and metastatic hormone-sensitive prostate cancer (PC). This analysis explores the efficacy and safety of leuprorelin in patients with PC and an indication for androgen deprivation therapy (ADT) in routine practice. Methods: Safety assessment focused...
View article titled, Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)
Open the PDF for Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN) in another window
Journal Articles

Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study

Open Access
Subject Area:
Further Areas
Bernd J. Schmitz-Dräger, Stephan Mühlich, Carsten Lange, Natalya Benderska-Söder, Ekkehardt Bismarck, Roland Starlinger, Bertram Ottillinger, Oliver W. Hakenberg
Journal: Urologia Internationalis
Urol Int (2021) 105 (5-6): 436–445.
https://doi.org/10.1159/000513073
Published Online: 25 February 2021
... is an open-label, non-interventional, multi-centre, German cohort study on leuprorelin in routine clinical practice. Objectives: To extend knowledge on the use, effectiveness, and tolerability of HEXAL/Sandoz leuprorelin (in this article, the term Leuprone® HEXAL® covers Leuprorelin Sandoz® as well) solid...
View article titled, Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study
Open the PDF for Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study in another window
Journal Articles

Intermittent Androgen Castration: A Biological Reality during Intermittent Treatment in Metastatic Prostate Cancer?

Available to Purchase
Subject Area:
Further Areas
N. Mottet, C. Lucas, E. Sene, C. Avances, L. Maubach, J.M. Wolff
Journal: Urologia Internationalis
Urol Int (2005) 75 (3): 204–208.
https://doi.org/10.1159/000087794
Published Online: 05 October 2005
... underwent a 6-months period of continuous maximal androgen blockade (MAB) consisting of leuprorelin (3.75 mg at monthly intervals) plus flutamide (250 mg t.i.d.) followed by IMAB. During each cycle, the cut-off prostate-specific antigen (PSA) levels to stop and resume treatment were 4 and 10 ng/ml...
View article titled, Intermittent Androgen Castration: A Biological Reality during Intermittent Treatment in Metastatic Prostate Cancer?
Open the PDF for Intermittent Androgen Castration: A Biological Reality during Intermittent Treatment in Metastatic Prostate Cancer? in another window
Journal Articles

Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate Cancer

Available to Purchase
Subject Area:
Further Areas
U.W. Tunn, U. Bargelloni, S. Cosciani, G. Fiaccavento, S. Guazzieri, F. Pagano
Journal: Urologia Internationalis
Urol Int (1998) 60 (Suppl. 1): 9–17.
https://doi.org/10.1159/000056540
Published Online: 26 March 1998
...-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations. Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively. In both groups, subcutaneous injections of leuprorelin acetate...
View article titled, Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate Cancer
Open the PDF for Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate Cancer in another window